Pathophysiological aspects of red blood cells in end‐stage renal disease patients resistant to recombinant human erythropoietin therapy
Modified, bioreactive red blood cells (RBCs) and RBC‐derived microvesicles (MVs) likely contribute to the hematological and cardiovascular complications in end‐stage renal disease (ESRD). This study assesses the physiological profile of RBCs in patients with ESRD receiving standard or high doses of recombinant human erythropoietin (rhEPO).
No Supplementary Data
No Article Media